Can-Fite BioPharma (CANF) AI Stock Analysis

• Market Cap: $15.60M
• Dividend Yield: N/A
• Average Volume (3M): 258.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 17,072,916
• 10 Day Avg. Volume: 432,468
• 30 Day Avg. Volume: 258,053
• PEG Ratio: 0.04
• Price to Book (P/B): 2.18
• Price to Sales (P/S): 17.54
• P/FCF Ratio: -1.55
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 9.96
• Enterprise Value/Gross Profit: 9.96
• Enterprise Value/Ebitda: -0.63
• 1Y Price Target: $2.50
• Price Target Upside: 541.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.37 ▼(-4.36% Downside)

Can-Fite BioPharma's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis also indicates weak momentum, with the stock trading below key moving averages. Valuation is difficult to assess due to the lack of earnings and dividends.

Positive Factors

Strategic Partnerships

Strategic partnerships, like with Vetbiolix, enhance Can-Fite's revenue potential through collaborations, expanding its market reach and product applications.

Intellectual Property Expansion

Securing patents in new regions strengthens Can-Fite's competitive position, protecting its innovations and opening new market opportunities.

Product Development Milestones

Achieving regulatory milestones for Namodenoson enhances its market potential, indicating strong therapeutic promise and expedited development pathways.

Negative Factors

Declining Revenue

Declining revenue trends indicate challenges in market penetration and sales growth, potentially impacting long-term financial stability and investment appeal.

Negative Cash Flow

Persistent negative cash flow suggests operational inefficiencies and reliance on external financing, posing risks to sustainability and strategic flexibility.

Decreasing Equity

Decreasing equity reflects potential erosion of financial stability, limiting the company's ability to invest in growth and withstand economic downturns.

Can-Fite BioPharma Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

How the Company Makes Money

Can-Fite BioPharma generates revenue through a combination of funding from research and development grants, strategic partnerships with pharmaceutical companies, and potential future product sales. The company seeks collaborations and licensing agreements with larger pharmaceutical firms, which can provide upfront payments, milestone payments based on the achievement of development stages, and royalties on future sales. Additionally, Can-Fite may receive funding from governmental or non-governmental organizations for specific research initiatives. The company's ongoing clinical trials and advancements in its product pipeline are critical factors influencing its revenue potential.

Can-Fite BioPharma Financial Statement Overview

Summary

Can-Fite BioPharma is facing significant financial challenges, with declining revenues, persistent losses, and reliance on external financing. Despite low leverage, the decreasing equity and continuous negative cash flow highlight potential sustainability risks.

Income Statement

Can-Fite BioPharma's income statement reveals significant challenges, with consistent negative EBIT and net income over the years, indicating ongoing operational inefficiencies. The company has experienced declining revenue, with a revenue decrease of approximately 9.3% from 2023 to 2024. Margins are negative, with a net profit margin of -1169% in 2024, highlighting profitability issues. Despite these challenges, the gross profit margin remains positive due to relatively low cost of goods sold.

Balance Sheet

The balance sheet shows a mixed picture. Can-Fite BioPharma maintains a low level of debt, with a debt-to-equity ratio of 0.019 in 2024, suggesting limited leverage risk. However, the stockholder's equity has been decreasing, indicating potential erosion in financial stability. The equity ratio stands at 59.6%, reflecting a moderate reliance on equity to finance assets. The decreasing equity may pose future risks if the trend continues.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which is a concern for sustainability. However, the free cash flow has improved by 9.5% from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that operations are not generating sufficient cash to cover net losses. The company has relied on financing activities to sustain operations, as seen with substantial financing cash flow in recent years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
Gross Profit	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
EBITDA	-8.90M	-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
Net Income	-8.80M	-7.88M	-7.63M	-10.17M	-12.60M	-14.44M
Balance Sheet
Total Assets	7.72M	9.12M	9.99M	9.28M	20.25M	9.52M
Cash, Cash Equivalents and Short-Term Investments	6.46M	7.89M	8.92M	7.98M	19.14M	8.34M
Total Debt	90.00K	104.00K	40.00K	62.00K	124.00K	67.00K
Total Liabilities	3.54M	3.68M	3.75M	4.81M	5.87M	3.45M
Stockholders Equity	4.18M	5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow
Free Cash Flow	-8.36M	-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
Operating Cash Flow	-8.35M	-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
Investing Cash Flow	-2.00K	1.50M	498.00K	9.50M	-14.51M	-26.00K
Financing Cash Flow	10.08M	6.71M	9.14M	0.00	20.46M	17.68M

Can-Fite BioPharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Neutral. The current price of 0.39 is above the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.48, and below the 200-day MA of 0.95, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 23.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CANF.

Can-Fite BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCDA	46 Neutral	$14.01M	-0.61	-317.47%	―	-100.00%	58.50%
PHGE	44 Neutral	$6.46M	-0.14	-154.50%	―	―	54.25%
CANF	43 Neutral	$15.60M	―	―	―	―	―
PCSA	29 Underperform	$17.42M	-0.15	-270.74%	―	―	72.88%

Can-Fite BioPharma Corporate Events

Can-Fite BioPharma Adjusts Warrant Terms to Enhance Market Appeal

On November 18, 2025, Can-Fite BioPharma Ltd. announced an agreement with a warrant holder to reduce the exercise price of warrants for 16,666,666 American Depositary Shares from $0.60 to $0.467 per ADS. This move, in exchange for the waiver of certain standstill provisions by the holder, could potentially enhance the attractiveness of the warrants and improve liquidity, reflecting a strategic decision to adjust financial terms in response to market conditions.

Can-Fite’s CF602 Secures Patent in Brazil for Erectile Dysfunction Treatment

On November 20, 2025, Can-Fite BioPharma Ltd. announced that its erectile dysfunction treatment, CF602, received a Notice of Allowance for a patent in Brazil. This patent expands CF602’s intellectual property protection beyond the U.S. and Europe, addressing a significant market need for diabetic patients and non-responders to existing ED drugs. CF602, an A3 adenosine receptor modulator, has shown promising results in preclinical studies, potentially offering an alternative to current ED treatments.

Can-Fite Achieves 9-Year Survival Milestone in Liver Cancer Treatment

On November 18, 2025, Can-Fite BioPharma Ltd. announced a significant milestone in its treatment of advanced liver cancer with Namodenoson. A patient treated in a Phase II study has achieved a 9-year survival with a complete response, remaining cancer-free. This breakthrough underscores Namodenoson’s potential as a potent anti-cancer agent with excellent tolerability. The company is currently enrolling patients for a pivotal Phase III trial in Europe, Israel, and the U.S., targeting hepatocellular carcinoma as a second or third-line treatment. Namodenoson holds Orphan Drug and Fast Track status with the FDA and EMA, highlighting its promising role in the liver cancer treatment market, which is projected to reach $6.1 billion by 2027.

Can-Fite BioPharma Shareholders Approve Key Proposals

On November 10, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders where all proposed resolutions were approved. This approval marks a significant step for the company as it aligns with their strategic plans and could potentially impact their market positioning and stakeholder interests.

Can-Fite BioPharma Reschedules Shareholder Meeting Due to Lack of Quorum

On November 3, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders, which was adjourned due to a lack of quorum. The meeting is rescheduled to reconvene on November 10, 2025, at the company’s offices in Ramat Gan, Israel. This adjournment may impact the company’s decision-making processes and timelines, potentially affecting its strategic operations and stakeholder interests.

Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring

On October 3, 2025, Can-Fite BioPharma Ltd. announced it will hold a Special General Meeting of Shareholders on November 3, 2025, at its offices in Ramat Gan, Israel. The meeting will address two key proposals: increasing the company’s authorized share capital by 22 billion shares and approving a reverse stock split at a ratio of 1:3000. These actions are intended to enhance the company’s capital structure and potentially improve its market position. Shareholders and American Depositary Shareholders are invited to vote on these proposals, which are recommended by the company’s Board of Directors.

Can-Fite BioPharma Announces Breakthrough in Liver Disease Treatment with Namodenoson

On September 15, 2025, Can-Fite BioPharma announced a significant clinical finding in its compassionate use program for decompensated liver cirrhosis. A patient treated with Namodenoson showed a complete resolution of esophageal varices, a severe complication of advanced liver disease. This outcome, confirmed by endoscopic evaluation, suggests a potential disease-modifying effect of Namodenoson. The drug is currently in Phase III trials for hepatocellular carcinoma and has shown promise in treating other conditions, highlighting its therapeutic potential in a market with limited treatment options.